1. What Is the Bioluminescence Imaging Market?
The Bioluminescence Imaging Market encompasses in vivo imaging systems, reagents, and genetically encoded reporter tools that detect light emitted from luciferase enzyme-substrate reactions in living organisms. They non-invasively visualise cell populations, gene expression, and biological processes in preclinical animal models. The market includes dedicated bioluminescence imaging cameras and imaging chambers, firefly and Renilla luciferase substrate reagents, and Nano-luciferase reporter reagents for bright bioluminescence at low enzyme expression. It also includes luciferase reporter gene constructs and bioluminescence resonance energy transfer detection systems. These platforms and reagents are used by pharmaceutical and academic oncology, infectious disease, and cell biology researchers to longitudinally track luciferase-expressing tumour cells, pathogens, and immune cell populations in living mouse models. They avoid sacrificing animals at each measurement time point. Market scope covers bioluminescence imaging hardware systems, luciferase substrate consumables, and luciferase reporter gene reagents and constructs for in vivo small animal bioluminescence imaging. It excludes fluorescence-only imaging systems, non-optical preclinical imaging modalities, and in vitro cell-based bioluminescence assay readers.
2. Bioluminescence Imaging Market Size & Forecast
3. Emerging Technologies
- Codon-optimised luciferase reporter construct libraries are advancing viral vector and plasmid expression systems with species-optimised codon usage that maximise luciferase protein expression per transfected cell in mammalian cell lines and primary cells. Growing BLI.
- Substrate delivery nanoparticle technology is advancing nanoparticle-encapsulated luciferin and coelenterazine formulations that improve substrate biodistribution to target organs after systemic injection, providing more uniform substrate delivery. Growing industry adoption of this technology is motivating development.
- Single-photon counting BLI detector technology is advancing ultra-sensitive EMCCD and sCMOS camera systems with single-photon counting sensitivity for detection of extremely dim bioluminescence from small reporter cell populations in deep tissue locations at reduced. Growing industry adoption of this technology is motivating development.
- BRET-based intracellular signalling biosensors are advancing bioluminescence resonance energy transfer systems using NanoLuc donor and fluorescent protein acceptor pairs that report protein-protein interactions, protein conformational changes, and second messenger concentrations as BLI. Growing pharmaceutical.
Such innovations are driving change across adjacent industries too. Discover more in our Small Animal Imaging Market.
4. Key Market Opportunity
A key opportunity in the Bioluminescence Imaging Market is the expansion of BLI reporter models for immuno-oncology drug development as the rapid growth of CAR-T cell, NK cell, and checkpoint inhibitor combination therapeutic programmes creates demand for in vivo immune cell tracking capabilities. A significant proportion of pharmaceutical immuno-oncology drug development programmes lack validated in vivo immune cell tracking models that can longitudinally monitor adoptive cell therapy distribution, tumour microenvironment infiltration, and persistence in the same animals throughout a treatment study. Bioluminescence-labelled CAR-T, NK cell, and tumour-infiltrating lymphocyte models that enable in vivo cell tracking provide pharmaceutical immuno-oncology teams with quantitative cell distribution and persistence data guiding dosing, scheduling, and combination strategy optimisation. BLI system manufacturers and luciferase reagent developers that provide validated immuno-oncology cell tracking protocols, pre-made luciferase-expressing immune effector cell products, and imaging analysis tools for immune cell distribution quantification are positioned to capture growing immuno-oncology BLI adoption.
5. Top Companies in the Bioluminescence Imaging Market
The following organisations hold leading positions in the Bioluminescence Imaging Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- PerkinElmer (IVIS)
- Promega (NanoLuc)
- Takara Bio (NightOWL)
- Spectral Instruments
- Berthold Technologies
- Caliper Life Sciences
- Gold Biotechnology
- AAT Bioquest
- Xenogen (PerkinElmer)
- BioVis
6. Market Segmentation
The Bioluminescence Imaging Market is analysed across 5 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Product Type | BLI Imaging System IVIS BLI System BLI Imaging Chamber Luciferase Substrate Reagent D-Luciferin Substrate Coelenterazine Renilla Nano-Luc Substrate Reporter Gene Construct Lentiviral Luciferase Vector AAV Luciferase Reporter BRET Detection System NanoBRET Luciferase Dual Reporter System Dual BLI Reporter Kit |
| By Luciferase Type | Firefly Luciferase Ppy FF Firefly CBRluc Click Beetle Red Renilla Luciferase hRluc Renilla Nano-Luciferase NanoLuc Bright Reporter Akaluc Reporter Akaluc NIR Reporter Oplophorus Luciferase OLuc Deep Red |
| By Application | Tumour Tracking BLI Xenograft Monitor Syngeneic BLI Tumour Infectious Disease Bacterial Pathogen BLI Viral BLI Reporter Immune Cell Tracking CAR-T BLI Tracking Gene Expression Reporter Gene BLI Drug Efficacy BLI Drug Efficacy Model |
| By End User | Pharmaceutical Companies Oncology BLI Research Academic Research Cancer Biology BLI Contract Research Organisations Preclinical CRO BLI Infectious Disease Research Pathogen BLI Research |
| By Geography | North America Europe Asia Pacific Latin America Middle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Bioluminescence Imaging Market trajectory over the forecast period:
Nano-Luciferase Technology Is Providing 100-Fold Brighter Bioluminescence Than Conventional Firefly Luciferase at Lower Reporter Gene Expression Levels.Pharmaceutical and academic researchers working with difficult-to-detect cell populations including rare cancer stem cells, metastatic tumour cell clusters, and low-frequency immune cell subsets in vivo are adopting NanoLuc. Akaluc bright bioluminescent reporters that emit 100 to 1000 times more photons per enzyme molecule than conventional firefly luciferase for improved detection sensitivity. Promega continued commercial development of NanoLuc luciferase substrate and reporter gene products in 2024. This provides researchers with validated bright bioluminescence reporter tools for applications requiring detection of low cell number or low gene expression targets in small animal BLI studies.
Multicolour Bioluminescence Imaging Is Enabling Simultaneous Tracking of Multiple Cell Populations in the Same Animal.Cancer immunology and drug combination researchers who need to simultaneously monitor tumour cell growth, immune effector cell infiltration, bystander cell populations. In the same living animal are adopting spectrally distinct dual-reporter bioluminescence imaging using blue-emitting coelenterazine Renilla luciferase and red-emitting click beetle luciferase simultaneously detected in the same imaging session. PerkinElmer continued commercial development of dual and multi-reporter BLI imaging protocols and spectral unmixing software for IVIS system multi-reporter imaging in 2024. This provides cancer immunology researchers with validated multi-reporter BLI imaging workflows for simultaneous tumour and immune cell population tracking.
Akaluc Near-Infrared Bioluminescence Technology Is Enabling Deep-TissueImaging Beyond the Depth Limit of Conventional Firefly Systems.Researchers imaging bioluminescent reporter expression in deep organs including liver, spleen, bone marrow, brain that are inaccessible at firefly luciferase emission wavelengths due to tissue absorption are adopting Akaluc reporter. This works with its substrate AkaLumine-HCl that emits bioluminescence at 650-700 nm Cl that emits bioluminescence at 650-700 nm, this provides superior tissue penetration in deep organs. Japan Science and Technology Agency and commercial reagent distributors continued academic Akaluc reagent access in 2024. Growing publications demonstrating improved deep-tissue bioluminescence detection in hepatic, splenic, and CNS targets compared with conventional firefly luciferase systems.
For related market intelligence, see the Preclinical Imaging Market.
8. Segmental Analysis
By product type, BLI imaging systems dominated the Bioluminescence Imaging Market in 2025, driven by the established IVIS system installed base at pharmaceutical and academic research facilities as the universal bioluminescence imaging hardware platform. Pharmaceutical and academic researchers continue specifying IVIS and similar BLI imaging chambers as the primary in vivo reporter imaging hardware as the photon-counting CCD platform provides quantitative bioluminescence detection for longitudinal tumour and cell tracking. Nano-luciferase reagents are the fastest-growing product type, driven by growing researcher adoption of NanoLuc and Akaluc bright reporters providing superior sensitivity for detecting small cell numbers and deep-tissue reporters over conventional firefly luciferase systems. Researchers are increasing NanoLuc and Akaluc substrate and reporter reagent adoption as brighter bioluminescence from advanced reporters improves detection sensitivity for rare cell population and deep-tissue BLI imaging without requiring instrument upgrades.
By application, tumour tracking dominated the Bioluminescence Imaging Market in 2025, driven by the large volume of preclinical oncology efficacy studies using luciferase reporter xenograft and syngeneic tumour models as the standard tumour monitoring method. Pharmaceutical oncology researchers continue generating the highest BLI demand for tumour tracking as luciferase bioluminescence provides non-invasive quantitative tumour growth data from living animals through longitudinal studies without sacrificing animals at each time point. Immune cell tracking is the fastest-growing application, driven by rapid expansion of immuno-oncology drug development requiring in vivo BLI monitoring of CAR-T cell distribution, NK cell trafficking, and tumour-infiltrating lymphocyte persistence in treatment models. Pharmaceutical immuno-oncology and adoptive cell therapy researchers are increasing BLI immune cell tracking adoption as longitudinal in vivo distribution data for luciferase-labelled therapeutic immune cells provides critical dosing guidance for cell therapy development.
9. Regional Analysis
Regional demand patterns across the Bioluminescence Imaging Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America accounted for the largest share of the Bioluminescence Imaging Market in 2025, holding 47.0% of the global market. The region's dominance reflects the large United States pharmaceutical oncology research community using luciferase xenograft tumour models as the standard preclinical tumour tracking approach, the high density of NIH-funded cancer biology academic programmes employing BLI reporter imaging, and the commercial headquarters of PerkinElmer and Promega as the leading BLI imaging and reagent manufacturers. The large United States pharmaceutical oncology research sector generates consistent IVIS system consumable and NanoLuc substrate demand as bioluminescence tumour tracking in xenograft and syngeneic mouse models is a standard endpoint in oncology drug candidate efficacy studies. Growing United States immuno-oncology research programmes using BLI-labelled CAR-T cells, NK cells, and tumour-infiltrating lymphocytes for in vivo cell distribution monitoring are expanding BLI reagent and imaging system demand beyond conventional solid tumour xenograft applications.
Highest CAGR Region
Asia Pacific is expected to register the highest CAGR of 13.00% during the forecast period. Growing pharmaceutical and academic oncology research investment in China, Japan, South Korea, and Australia creating demand for in vivo BLI reporter tumour models, expanding university and pharmaceutical research centre BLI imaging facility installation, and increasing use of luciferase reporter infectious disease and cell biology models across the region are driving BLI market growth. Growing Chinese pharmaceutical company oncology drug discovery investment is creating demand for IVIS bioluminescence imaging systems as luciferase reporter xenograft models become standard tools in Chinese pharmaceutical oncology research programmes. Growing South Korean and Japanese academic cancer biology programme investment in advanced in vivo imaging capability is creating consistent BLI system and consumable demand at university cancer research centres managing growing oncology and immuno-oncology research caseloads.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology Adoption Trends and Innovation Tracking
- • Custom Company Profiling and Benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country-Level Opportunity Mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Bioluminescence Imaging Market was valued at USD 564.35 Mn in 2025 and is projected to reach USD 1,330.59 Mn by 2034, growing at a CAGR of 10.00% over the 2026–2034 forecast period.
The Bioluminescence Imaging Market is projected to grow at a CAGR of 10.00% from 2026 to 2034.
North America accounted for the largest share of the Bioluminescence Imaging Market in 2025, holding 47.0% of the global market.
The leading companies in the Bioluminescence Imaging Market include PerkinElmer (IVIS), Promega (NanoLuc), Takara Bio (NightOWL), Spectral Instruments, Berthold Technologies, Caliper Life Sciences, Gold Biotechnology, AAT Bioquest, Xenogen (PerkinElmer), BioVis.
Nano-luciferase technology is providing 100-fold brighter bioluminescence than conventional firefly luciferase at lower reporter gene expression levels.
By product type, BLI imaging systems dominated the Bioluminescence Imaging Market in 2025, driven by the established IVIS system installed base at pharmaceutical and academic research facilities as the universal bioluminescence imaging hardware platform.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.